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Acute Chagas disease is characterized by a systemic infection that leads to the strong acti-
vation of the adaptive immune response. Outbreaks of oral contamination by the infective
protozoan Trypanosoma cruzi are frequent in Brazil and other Latin American countries,
and an increased severity of clinical manifestations and mortality is observed in infected
patients. These findings have elicited questions about the specific responses triggered
after T. cruzi entry via mucosal sites, possibly modulating local immune mechanisms, and
further impacting regional and systemic immunity. Here, we provide evidence for the exis-
tence of differential lymphoid organ responses in experimental models of acute T. cruzi
infection.
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Chagas disease (American Trypanosomiasis) is a neglected trop-
ical illness caused by the hemoflagellate protozoan Trypanosoma
cruzi. This infection is considered a world-wide health problem
with a lack of treatment options due to the absence of a vaccine
and global spreading (1, 2). Trypanosoma cruzi infection was ini-
tially endemic in rural areas of Latin America and, transmitted
by contaminated insect vectors of the Reduviidae family. Insects
become vectors after biting T. cruzi-infected animals or humans.
The parasite can also be directly transmitted by blood transfusion
and organ transplantation as well as orally and congenitally (3,
4). The incubation period (the time between T. cruzi exposure
and development of symptoms) varies according to the infection
route; for example, transmission by vector has an incubation time
of 4–15 days. In cases of transfusion the incubation time ranges
from 8 to 120 days, whereas in congenital transmission it varies
from 3 to 22 days; roughly the same for oral transmission (5, 6).
Today, the oral infection is the most common transmission route
in the Brazilian Amazon region after the pan-American Health
Organization declared the abrogation of vectorial transmission in
the area (5). Interestingly, oral transmission has been associated
with high mortality and morbidity due to an increased prevalence
and severity of cardiac pathology (myocarditis) (7–10).
TRYPANOSOMA CRUZI INFECTION TARGETS SEVERAL
TISSUES IN THE HOST
During the acute phase of the disease, the parasites highly replicate
in tissues (under amastigote form), and infective trypomastig-
ote forms are numerous in the blood. Throughout this phase, T.
cruzi is able to infect many host tissues, including skeletal mus-
cle, lymphoid and nervous tissues, endocrine glands, and mucose
(Table 1).
In immunocompetent hosts, the high parasitemia observed in
the acute phase is quickly controlled through immune effector
mechanisms. As a result, T. cruzi numbers in the blood and tis-
sues drop drastically to almost undetectable levels as the infected
individual enters the chronic phase. Nevertheless, in situ PCR
(Polymerase Chain Reaction) and confocal analyses have shown
that even in the chronic phase, tissues are not parasite-free (11–
18). Several tissues, including the heart and the nervous system,
as well as adipocytes, retain amastigote forms that perpetuate
the chronic infection (19–21). Additionally, Chagas disease may
be reactivated during periods of immunosuppression, such as in
patients with HIV/AIDS or undergoing immunosuppressive drug
therapy (22, 23).
Although controlled,T. cruzi persistence in tissues appears to be
associated with inflammatory lesions and disease severity in the
chronic phase (12, 13, 18, 24–28). Using two models of chronic
infection, Zhang and Tarleton (18) demonstrated that parasite
clearance from tissues resulted in the disappearance of associated
inflammatory lesions and resolution of disease. Taken together,
these studies clearly demonstrate that Chagas disease is a systemic
infection and that the immune response is important in contain-
ing T. cruzi replication in the acute phase which impacts disease
severity during the chronic phase of the infection.
SYSTEMIC OR MUCOSAL ROUTES OF T. CRUZI INFECTION
DIFFERENTIALLY AFFECT PARASITE LOAD AND MORTALITY
IN MICE
Experimental models of T. cruzi infection have been widely used
to study various aspects of the pathogenesis and pathophysiol-
ogy of Chagas disease. In fact, the vast majority of our knowl-
edge on the biology of T. cruzi infection was initially obtained
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Table 1 |Tissue infectivity ofTrypanosoma cruzi in mammals.
Target tissue Human Animals
Acute Chronic Acute (4–50dpi) Chronic (60–730dpi)
Adipose tissue ND Ferreira et al. (21) Andrade and Silva (76), Buckner et al. (77),
Guarner et al. (78), Combs et al. (20)
Guarner et al. (78), Combs
et al. (20)
Adrenal gland ND ND Buckner et al. (77), Correa-de-Santana et al.
(79)
ND
Blood Qvarnstrom et al.
(80)
Moreira et al. (11),
Qvarnstrom et al.
(80)
Hoft et al. (69), Buckner et al. (77), Cortez et
al. (81), Guillermo et al. (55), Silva et al. (57),
Veloso et al. (82), Castro-Sesquen et al. (83)
Veloso et al. (82),
Castro-Sesquen et al. (83)
Bone ND ND Morocoima et al. (84) ND
Bone marrow Baena Teran et al.
(85)
ND Morocoima et al. (84) ND
Cartilage ND ND Da Costa et al. (86), Morocoima et al. (84) ND
Central Nervous
System
Mortara et al. (19) Mortara et al. (19) Andrade et al. (87), Buckner et al. (77),
Guarner et al. (78), Rachid et al. (88)
Andrade et al. (87),
Guarner et al. (78)
Gastro Intestinal
Tract
Mortara et al. (19) ND Andrade et al. (87), Buckner et al. (77),
Guarner et al. (78)
Andrade et al. (87),
Guarner et al. (78)
Heart Mortara et al. (19) Mortara et al. (19),
Vago et al. (89),
Schijman et al. (90)
Andrade et al. (87), Buckner et al. (77),
Guarner et al. (78), Combs et al. (20),
Castro-Sesquen et al. (83)
Guarner et al. (78), Combs
et al. (20), Castro-Sesquen
et al. (83)
Liver ND ND Hoft et al. (69), Buckner et al. (77), Guarner et
al. (78)
ND
Lung Mortara et al. (19) ND Guarner et al. (78) Guarner et al. (78)
Lymph nodes ND ND Hoft et al. (69), Guarner et al. (78), Giddings
et al. (74)
Guarner et al. (78)
Muscle ND ND Buckner et al. (77), Guarner et al. (78) Buckner et al. (77),
Guarner et al. (78)
Pancreas ND ND Guarner et al. (78) Guarner et al. (78)
Peritoneal cells ND ND Silva et al. (57) ND
Skin (19) Mortara et al. (19) ND ND
Spleen ND ND Hoft et al. (69), Buckner et al. (77), Guarner et
al. (78), Combs et al. (20), Giddings et al. (74)
Guarner et al. (78), Combs
et al. (20)
Stomach/esophagus ND Vago et al. (91) Hoft et al. (69), Guarner et al. (78), Cortez et
al. (81), Staquicini et al. (92)
Guarner et al. (78)
Thymus ND ND Da Costa et al. (86) ND
kidney (19) ND Buckner et al. (77), Guarner et al. (78),
Castro-Sesquen et al. (83)
Guarner et al. (78),
Castro-Sesquen et al. (83)
nasal cavity ND ND Giddings et al. (74) ND
Bladder ND ND Buckner et al. (77) Buckner et al. (77)
ND – not detected.
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using experimental mouse models. It is well established that the
immune response and immunopathologic manifestations follow-
ing T. cruzi infection are dependent on genetically heterogeneous
host populations, parasite strain, inoculum size, and route of infec-
tion. Moreover, the anatomical route of pathogen invasion may
directly impact upon the host immune response and host resis-
tance (Box 1). In this way, several studies compared mucosal and
systemic T. cruzi infection and mortality in mice.
In 1967, Marsden showed that CFI mice infected with the Peru-
vian strain of T. cruzi by systemic routes [intraperitoneal (i.p.),
intravenous (i.v.), or subcutaneous (s.c.)] showed higher infection
rates (67–100%) and mortality than mucosal routes [oral (o.i.),
intragastric (i.g.), intrarectal (i.r.), genitalia (gen.), or conjunctival
(cnj.)] (17–67%) (29). Similar results were observed in a study by
Camandaroba et al. (30) in which i.p. and i.g. inoculation with
the Peruvian and Colombian strains of T. cruzi were compared in
Swiss mice. Caradonna and Pereiraperrin (31) infected BALB/c
and C57BL/6 mice with the Tulahuén strain of T. cruzi via s.c.
and intranasal (i.n.) routes and observed higher mortality in the
s.c. group. Interestingly, mice infected via the i.n. route developed
higher brain parasitism and lower blood parasitemia than animals
infected via the s.c. route, suggesting a preferential homing of the
parasite to the brain after i.n. administration (31).
Taken together, these observations suggest that the route of
parasite entry into the host is a key factor in Chagas pathogenesis.
It is logical to think that following parasite entry, the initial tar-
get tissues/cells in the circulation (Table 2) may contribute to the
development of an immune response able to control infection.
SYSTEMIC TRYPANOSOMA CRUZI ENTRY INDUCES A
DIFFERENTIAL RESPONSE IN SECONDARY LYMPHOID
ORGANS OF INFECTED MICE
Acute and chronic T. cruzi infections promote significant increases
in the size and numbers of cells in the subcutaneous lymph nodes
(SCLN) and spleen (SP), likely due to persistent T and B cell poly-
clonal activation in these tissues (32, 33). Parasite-derived proteins,
such as trans-sialidase and racemase, as well as T. cruzi-derived
DNA have been shown to contribute to lymphocyte proliferation
in Chagas disease (34–36). Interestingly, the majority of poly-
clonal lymphocytes activated during early T. cruzi infection do
not appear to be parasite-specific (37–45). However, the relative
role of T and B cells in controlling T. cruzi infection remains
controversial. Although there are data showing that T and B cell
activation is necessary for limiting T. cruzi expansion, the poly-
clonal activation also appears to contribute to the pathological
alterations observed in Chagas disease (44, 46, 47). Similarly to
splenocytes, SCLN-derived effector T cells from infected mice
secrete high amounts of IL-2, IL-4, IL-10, and IFN-γ, suggest-
ing the existence of a mixed type-1 and type-2 profiles of cytokine
secretion (48, 49).
The process of expansion and contraction by the lymphocyte
population in the secondary lymphoid organs can be regarded as
a regional response to systemic T. cruzi infection. Gut-associated
lymphoid tissues are specialized for draining antigens present in
the gastrointestinal tract and are also involved in the tolerogenic
immune response. In this respect, gut-associated lymphoid tis-
sues may be involved in the progressive damage of the digestive
Box 1 T cell differentiation into effector cells following bacte-
rial infections may be differentially programed depending on
the route of pathogen presentation (96, 97).
Accordingly, intravenous infection generates IFN-γ-producing T
cells, whereas the mucosal routes of infection (e.g., intranasal
or intragastric) generate IL-17-producing T cells. These results
are in keeping with the observation that spleen-derived antigen-
presenting (APC) cells are prone to producing IL-12, a cytokine
involved in Th1 differentiation, whereas mucosal APC rather pro-
duce IL-6 and TGF-β, cytokines that selectively drive the Th17
differentiation program (98). In addition, it is interesting to note
that these route-driven programs of T cell differentiation may
be involved in the fine tuning of innate receptors for bacterial
molecules (96) and influence the ability to generate an efficient
memory pool of effector cells (97).
Table 2 | Primary distribution ofT. cruzi in infected mice.
Route of infection First target tissues/cells Reference
Intravenous Blood, liver, spleen, lungs, and
kidneys/macrophages
Kuhn et al. (93)
Intraperitoneal Peritoneal macrophages Nogueira et al. (94)
Oral Stomach (epithelial cells),
drainage lymph node
Hoft et al. (69),
Yoshida (95)
Conjunctival Nasolacrimal ducts and nasal
cavities (epithelial cells), parotid,
and submandibular lymph node
Giddings et al. (74)
system (megacolon and megaesophagus) that is a consequence of
chronic T. cruzi infection (50–52). For these reasons, the mesen-
teric lymph nodes (MLN) and Peyer’s Patches (PP) are also studied
in systemic infections, since they may be involved in the gut patho-
logical changes that are observed in infected patients. In contrast
to the hyperplasia of the SP and SCLN observed in infected mice,
there is a reduction in the size and cell number of the MLN and PP,
possibly due to the increased depletion of T and B lymphocytes
(49, 53, 54).
As a consequence of cell activation, T lymphocyte apoptosis is
also observed in lymphoid tissues (Box 2). In fact, the Fas mole-
cule is one candidate to regulate T and B lymphocyte responses in
both the SP and SCLN during the acute infection (33, 54, 55). For
example, it has been shown that Fas selectively kills activated IgG+
B lymphocytes with specificities for parasite antigens (56). More-
over, SP-derived CD4+ and CD8+ T cells respond to Fas-induced
apoptosis, as they demonstrate increased Fas/FasL expression and
caspase-8 activation during acute infection (48, 55). In agreement
with these data, it has been shown that the in vivo injection of
anti-FasL and a general caspase inhibitor (zVAD-fmk) into acutely
infected mice impairs T and B lymphocyte death and improves the
host immune response to infection in both SCLN and SP (55, 57).
Blockade of activated CD8+ T cell death increases IFN-γ secretion
by splenocytes in the initial stages of infection, and IL-4 and IL-10
are induced at later stages (55, 58).
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Box 2 T cell apoptosis can be stimulated in secondary
lymphoid organs by features such as activation-induced
cell death (AICD), granzymes, or growth factor withdrawal
(59, 60).
The abundance of antigens and cytokine production (IL-2) in the
microenvironment is essential to trigger the cell death pathway
(60). In the presence of a given antigen, IL-2 prompt T cells to die
by AICD, through activation of death receptor molecules (Fas or
TNF-R and caspase-8 activation) (61–63). The absence of antigen,
deprivation of cytokines or cytotoxic factors (such as oxidative
stress and glucocorticoids) initiates the intrinsic apoptotic path-
way, regulated by anti-apoptotic BCL-2 family members that can
be divided into three subgroups of proteins: (1) the pro-survival
members (Bcl-2, Bcl-xL, Mcl-1, A1/Bfl-1, and Bcl-w); (2) the pro-
apoptotic BH3-only proteins (Bim, Bid, Puma, Bad, Bmf, Hrk,
Bik, and Noxa) activated transcriptionally, post-transcriptionally, or
post-translationally by cytotoxic factors; and (3) multi-BH domain
pro-apoptotic protein (Bak and Bax) (64–67). The intrinsic path-
way of death involves mitochondrial membrane permeabilization,
cytochrome c release into the cytoplasm, activation of caspase-9,
and downstream effector caspases (61). Interestingly, regulatory
T cells deprives the effectorT cells of growth factors (such as IL-2),
which causes either proliferation arrest and apoptosis mediated
by growth factor withdrawal (59, 68).
Diminished numbers of MLN and PP lymphocytes from T.
cruzi-infected mice appear to be associated with differences in
lymphocyte activation, proliferation, and apoptosis. MLN-derived
cells from infected mice show reduced numbers of proliferating
lymphocytes in vivo and decreased cytokine production (IL-2,
IL-4, IL-10) in vitro by activated T cells, which have been demon-
strated to produce mainly type-1 cytokines (33, 49). In addition to
Fas, TNFR1/p55-mediated signaling and IL-4 deprivation through
caspase-9 activation are involved in T cell death and consequent
MLN atrophy seen in the course of acute infection (33, 49). These
data suggest that distinct mechanisms are involved in lymphocyte
contraction events.
These studies demonstrated that lymphocyte apoptosis in sec-
ondary lymphoid organs represents an important feature of the
immune response to a given pathogen. In agreement, the in vivo
administration of zVAD-fmk reduces lymphocyte apoptosis in sec-
ondary lymphoid tissues and increases host resistance to T. cruzi
infection (49). Moreover, SP or MLN cells are involved in the host
immune response, as splenectomy or MLN excision prior to T.
cruzi infection in mice increases susceptibility to infection with
elevated blood parasitemia (49, 54). In this context, further stud-
ies are necessary to approach apoptosis-associated molecules that
might be operating as a consequence of regional response fol-
lowing T cell activation and regulation in the course of T. cruzi
infection (Box 2).
DOES A DISTINCT ROUTE OF INFECTION INTERFERE WITH
SECONDARY LYMPHOID ORGAN DYNAMICS?
Previous data have revealed that oral T. cruzi inoculation results
in blood parasitemia and heart tissue parasitism, thereby clearly
indicating a systemic infection (30, 69, 70). A primary infection
with insect-derived infective forms delivered orally resulted in par-
asite replication within epithelial cells of the gastric mucosa (69).
This initial invasion is related to establishment of a progressive
gastritis and allows further systemic dissemination of the para-
site. Nonetheless, the short replication period at this mucosal site
induces specific immunity, as protection was observed after a sec-
ondary mucosal challenge. Such protection apparently involves
the specific production of IgA and IgG (69) and possibly employs
CCR5-CCL5 signaling (71).
Protection may also be due to IFN-γ-producing lymphocytes as
indicated by their increased frequency in the gastric mucosa and
draining lymph nodes of orally infected mice (69). Moreover, a
mucosal vaccination approach leading to polarized type-1 or type-
2 responses (72) as well as the mucosal challenge of genetically
deficient mice (73) reinforced the central role for a type-1 response
in providing protection following mucosal infection. Interestingly,
these humoral and cellular responses are also protective after par-
asite inoculation in the conjunctival mucosa, a natural portal of
entry for T. cruzi that leads to nasal infection with subsequent
systemic spreading (74).
Following outbreaks of oral contamination by T. cruzi, a clear
increase in the severity of clinical manifestations was observed
in infected patients compared with other types of transmission
routes (7, 75). These observations raise important questions con-
cerning the particular features of T. cruzi entry via the mucosa,
including the possible modulation of local immune mechanisms
and the impact on regional and systemic immunity. In fact, we
have previously shown that mice infected via both the i.p. and
s.c. routes show similar parasitemia and induce SCLN expan-
sion as well as MLN atrophy (33). Interestingly, the s.c. route
induced higher SCLN cell expansion and similar MLN atro-
phy at the peak of parasitemia when compared with the i.p.
route. These data suggest that unlike SCLN cells, MLN lympho-
cytes are similarly affected upon infection using both inoculation
routes (33).
One can argue that an oral or intragastric infection might
impact more severely on the mucosal associated lymphoid organs
than the SCLN and SP. We still lack information regarding SCLN
behavior in oral infection, but hyperplasia of the lymphoid fol-
licles in the SP has been reported (30). Additionally, Hoft et al.
(69) showed that after oral T. cruzi infection, BALB/c mice had
an increase in gastric lymph node size. In this study, the analysis
of cytokine production by gastric lymph node cells and spleno-
cytes showed that IFN-γ and IL-4 were produced in these tissues.
These data indicate that in both systemic and mucosal infections
splenocytes exhibit a mixed type-1 and type-2 profile of cytokine
secretion (48, 49, 69). Regarding the MLN response upon oral
infection, no data have been reported in the literature. Therefore,
a comparative analysis of oral infections versus other infection
routes should be critically performed to better understand the
immune mechanisms that are involved in the response to mucosal
T. cruzi infection.
CONCLUSION AND PERSPECTIVES
Chagas disease is characterized by both protective and
immunopathogenic responses. An antigenic challenge in the
host elicits a complex protective immune response that includes
both inflammatory and regulatory networks. These networks
are observed after T. cruzi infection and are induced due to
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systemic infection. However, different routes of parasite entry may
impact these immune circuits, define particular regional immune
responses, and perhaps change the existing view of how the host
mounts a protective immune response. Thus, the current micro-
epidemic of the oral transmission of Chagas disease prompts
revisiting previous findings (99). More importantly, new studies
investigating the influence of a primary infection with the parasite
through mucose should be performed.
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